A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

PHASE2TerminatedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

January 6, 2024

Study Completion Date

May 16, 2024

Conditions
Alopecia Areata
Interventions
DRUG

Deucravacitinib

Specified dose on specified days

OTHER

Placebo

Placebo was administered.

Trial Locations (28)

2217

Local Institution - 0003, Kogarah

3053

Local Institution - 0005, Carlton

75010

Local Institution - 0020, Paris

78759

Local Institution - 0012, Austin

84095

Local Institution - 0017, South Jordan

90404-2120

Local Institution - 0016, Santa Monica

06510

Local Institution - 0036, New Haven

33624-2038

Local Institution - 0018, Tampa

48038-1137

Local Institution - 0023, Clinton Township

10029-6501

Local Institution - 0024, New York

27516-4061

Local Institution - 0019, Chapel Hill

97201-5134

Local Institution - 0011, Portland

15213-3403

Local Institution - 0032, Pittsburgh

77004-8098

Local Institution - 0013, Houston

78213-2250

Local Institution - 0014, San Antonio

R3M 3Z4

Local Institution - 0015, Winnipeg

L3P 1X2

Local Institution - 0021, Markham

K9J 5K2

Local Institution - 0009, Peterborough

L4C 9M7

Local Institution - 0010, Richmond Hill

H2X 2V1

Local Institution - 0034, Montreal

G1V 4X7

Local Institution - 0027, Québec

06200

Local Institution - 0033, Nice

431-3192

Local Institution - 0031, Hamamatsu

136-0075

Local Institution - 0028, Kōtoku

181-8611

Local Institution - 0030, Mitaka-Shi

160-0023

Local Institution - 0029, Shinjuku-Ku

50-566

Local Institution - 0026, Wroclaw

02-962

Local Institution - 0025, Warsaw

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05556265 - A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata | Biotech Hunter | Biotech Hunter